Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 540

1.

Spontaneous echo contrast mimicking aortic root thrombus in a patient supported with extracorporeal membrane oxygenation.

De Bono JA, McGiffin DC, Waldron BJF, Leet AS, Doi A.

Echocardiography. 2019 Jan 16. doi: 10.1111/echo.14265. [Epub ahead of print]

PMID:
30652359
2.

Survival after cardiac resynchronization therapy: results from 50 084 implantations.

Leyva F, Zegard A, Okafor O, de Bono J, McNulty D, Ahmed A, Marshall H, Ray D, Qiu T.

Europace. 2018 Dec 27. doi: 10.1093/europace/euy267. [Epub ahead of print]

PMID:
30590500
3.

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK.

J Clin Oncol. 2018 Dec 21:JCO1801279. doi: 10.1200/JCO.18.01279. [Epub ahead of print]

PMID:
30576268
4.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30932-1. doi: 10.1016/j.eururo.2018.11.033. [Epub ahead of print]

5.

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H.

Mol Cell. 2019 Jan 3;73(1):22-35.e6. doi: 10.1016/j.molcel.2018.10.034. Epub 2018 Dec 6.

PMID:
30527665
6.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1. Review.

PMID:
30507436
7.

EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, Rengel-Puertas A, Ouhlen M, Crespo M, Berghuis AMS, Andree KC, Vidotto R, Trapp EK, Tzschaschel M, Colomba E, Fowler G, Flohr P, Rescigno P, Fontes MS, Zamarchi R, Fehm T, Neubauer H, Rack B, Alunni-Fabbroni M, Farace F, De Bono J, IJzerman MJ, Terstappen LWMM.

Oncotarget. 2018 Nov 2;9(86):35705-35716. doi: 10.18632/oncotarget.26298. eCollection 2018 Nov 2.

8.

Immunotherapy for lethal prostate cancer.

Rescigno P, de Bono JS.

Nat Rev Urol. 2018 Nov 22. doi: 10.1038/s41585-018-0121-y. [Epub ahead of print] No abstract available.

PMID:
30467373
9.

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.

Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG.

Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30855-8. doi: 10.1016/j.eururo.2018.11.001. [Epub ahead of print]

PMID:
30466891
10.

Eligibility for subcutaneous implantable cardioverter defibrillators in the adult congenital heart disease population.

Garside H, Leyva F, Hudsmith L, Marshall H, de Bono J.

Pacing Clin Electrophysiol. 2019 Jan;42(1):65-70. doi: 10.1111/pace.13537. Epub 2018 Dec 4.

PMID:
30394548
11.

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles.

Nanou A, Crespo M, Flohr P, De Bono JS, Terstappen LWMM.

Cancers (Basel). 2018 Oct 31;10(11). pii: E416. doi: 10.3390/cancers10110416.

12.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

13.

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.

Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS.

Eur Urol. 2019 Jan;75(1):184-192. doi: 10.1016/j.eururo.2018.09.048. Epub 2018 Oct 16.

14.

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.

Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR.

J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.

15.

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA.

Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15.

PMID:
30318518
16.

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.

Ingles Garces AH, Ang JE, Ameratunga M, Chénard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U.

Eur J Cancer. 2018 Nov;104:32-38. doi: 10.1016/j.ejca.2018.08.019. Epub 2018 Oct 10.

17.

RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.

Nava Rodrigues D, Casiraghi N, Romanel A, Crespo M, Miranda S, Rescigno P, Figueiredo I, Riisnaes R, Carreira S, Sumanasuriya S, Gasperini P, Sharp A, Mateo J, Makay A, McNair C, Schiewer M, Knudsen K, Boysen G, Demichelis F, de Bono JS.

Clin Cancer Res. 2019 Jan 15;25(2):687-697. doi: 10.1158/1078-0432.CCR-18-2068. Epub 2018 Sep 26.

PMID:
30257982
18.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4.

19.

Alternative splicing in prostate cancer.

Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J, Plymate SR, de Bono JS.

Nat Rev Clin Oncol. 2018 Nov;15(11):663-675. doi: 10.1038/s41571-018-0085-0. Review.

PMID:
30135575
20.

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.

Eur Urol. 2018 Aug 14. pii: S0302-2838(18)30557-8. doi: 10.1016/j.eururo.2018.07.035. [Epub ahead of print] Review.

21.

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, Chandler R, Mehra N, Fowler G, Ebbs B, Flohr P, Miranda S, Yuan W, Mackay A, Ferreira A, Pereira R, Bertan C, Figueiredo I, Riisnaes R, Rodrigues DN, Sharp A, Goodall J, Boysen G, Carreira S, Bianchini D, Rescigno P, Zafeiriou Z, Hunt J, Moloney D, Hamilton L, Neves RP, Swennenhuis J, Andree K, Stoecklein NH, Terstappen LWMM, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5635-5644. doi: 10.1158/1078-0432.CCR-18-0862. Epub 2018 Aug 9.

PMID:
30093450
22.

Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, de Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Sep;50(9):1343. doi: 10.1038/s41588-018-0181-1.

PMID:
30089860
23.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2018 Nov;82(5):757-766. doi: 10.1007/s00280-018-3661-1. Epub 2018 Aug 7.

24.

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, Figueiredo I, Ferreira A, Christova R, Gil V, Aziz S, Bertan C, de Oliveira FM, Atkin M, Clarke M, Goodall J, Sharp A, MacDonald T, Rubin MA, Yuan W, Barbieri CE, Carreira S, Mateo J, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5585-5593. doi: 10.1158/1078-0432.CCR-18-0937. Epub 2018 Aug 1.

PMID:
30068710
25.

Health economic impact of liquid biopsies in cancer management.

IJzerman MJ, Berghuis AMS, de Bono JS, Terstappen LWMM.

Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):593-599. doi: 10.1080/14737167.2018.1505505. Epub 2018 Aug 7.

PMID:
30052095
26.

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.

Sundar R, Miranda S, Rodrigues DN, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez DR, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J.

Clin Colorectal Cancer. 2018 Dec;17(4):280-284. doi: 10.1016/j.clcc.2018.05.011. Epub 2018 Jun 8.

27.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel PH, Maslyar DJ, Jinga V.

Clin Cancer Res. 2018 Jul 23. doi: 10.1158/1078-0432.CCR-18-0981. [Epub ahead of print]

PMID:
30037818
28.

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.

Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.

29.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.

Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U.

Ann Oncol. 2018 Sep 1;29(9):1918-1925. doi: 10.1093/annonc/mdy245.

30.

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).

Andree KC, Mentink A, Zeune LL, Terstappen LWMM, Stoecklein NH, Neves RP, Driemel C, Lampignano R, Yang L, Neubauer H, Fehm T, Fischer JC, Rossi E, Manicone M, Basso U, Marson P, Zamarchi R, Loriot Y, Lapierre V, Faugeroux V, Oulhen M, Farace F, Fowler G, Sousa Fontes M, Ebbs B, Lambros M, Crespo M, Flohr P, de Bono JS.

Int J Cancer. 2018 Nov 15;143(10):2584-2591. doi: 10.1002/ijc.31752. Epub 2018 Sep 19.

PMID:
30006930
31.

Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.

Rescigno P, Chandler R, de Bono J.

Curr Opin Support Palliat Care. 2018 Sep;12(3):339-343. doi: 10.1097/SPC.0000000000000358.

PMID:
29979319
32.

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.

Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D.

Nature. 2018 Jul;559(7713):285-289. doi: 10.1038/s41586-018-0291-z. Epub 2018 Jul 4.

33.

Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.

Plymate SR, Sharp A, de Bono JS.

JAMA Oncol. 2018 Sep 1;4(9):1187-1188. doi: 10.1001/jamaoncol.2018.1615. No abstract available.

PMID:
29955776
34.

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A.

Nature. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27.

PMID:
29950727
35.

Decompensated Heart Failure With Ventricular Arrhythmia: How Useful Is VT Ablation?

Dimitropoulos G, Leventogiannis G, De Bono J.

Curr Heart Fail Rep. 2018 Jun 25. doi: 10.1007/s11897-018-0395-7. [Epub ahead of print] Review.

PMID:
29938322
36.

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.

Rescigno P, Lorente D, Dolling D, Ferraldeschi R, Rodrigues DN, Riisnaes R, Miranda S, Bianchini D, Zafeiriou Z, Sideris S, Ferreira A, Figueiredo I, Sumanasuriya S, Mateo J, Perez-Lopez R, Sharp A, Tunariu N, de Bono JS.

Eur Urol Oncol. 2018 May;1(1):71-77. doi: 10.1016/j.euo.2018.02.006.

37.

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM.

Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034.

38.

Reply to C. Ren et al.

Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon-Carrera A, Fizazi K, Fleisher M, de Bono JS, Scher HI.

J Clin Oncol. 2018 Aug 1;36(22):2354-2356. doi: 10.1200/JCO.2018.78.2672. Epub 2018 Jun 12. No abstract available.

PMID:
29894273
39.

Hypoxia and Noncoding RNAs in Taxane Resistance.

Pucci P, Rescigno P, Sumanasuriya S, de Bono J, Crea F.

Trends Pharmacol Sci. 2018 Aug;39(8):695-709. doi: 10.1016/j.tips.2018.05.002. Epub 2018 Jun 8. Review.

PMID:
29891252
41.

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E.

Br J Cancer. 2018 May;118(11):1425-1433. doi: 10.1038/s41416-018-0082-1. Epub 2018 May 16.

42.

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.

Lorente D, Olmos D, Mateo J, Dolling D, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, Scher HI, Terstappen LWMM, de Bono JS.

Ann Oncol. 2018 Jul 1;29(7):1554-1560. doi: 10.1093/annonc/mdy172.

PMID:
29741566
43.

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.

Nanou A, Coumans FAW, van Dalum G, Zeune LL, Dolling D, Onstenk W, Crespo M, Fontes MS, Rescigno P, Fowler G, Flohr P, Brune C, Sleijfer S, de Bono JS, Terstappen LWMM.

Oncotarget. 2018 Apr 10;9(27):19283-19293. doi: 10.18632/oncotarget.25019. eCollection 2018 Apr 10.

44.

Metastatic Prostate Cancer.

Sartor O, de Bono JS.

N Engl J Med. 2018 Apr 26;378(17):1653-1654. doi: 10.1056/NEJMc1803343. No abstract available.

PMID:
29694820
45.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
46.

Second-generation antiandrogens in nonmetastatic CRPC.

Chandler R, de Bono J.

Nat Rev Urol. 2018 Jun;15(6):342-344. doi: 10.1038/s41585-018-0007-z. No abstract available.

PMID:
29666457
47.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

PMID:
29662167
48.

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Coleman N, Michalarea V, Alken S, Rihawi K, Lopez RP, Tunariu N, Petruckevitch A, Molife LR, Banerji U, De Bono JS, Welsh L, Saran F, Lopez J.

J Neurooncol. 2018 Aug;139(1):107-116. doi: 10.1007/s11060-018-2847-z. Epub 2018 Apr 10.

PMID:
29637509
49.

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

McVeigh TP, Sundar R, Diamantis N, Kaye SB, Banerji U, Lopez JS, de Bono J, van der Graaf WTA, George AJ.

Eur J Cancer. 2018 May;95:20-29. doi: 10.1016/j.ejca.2018.02.028. Epub 2018 Mar 31.

50.

The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM; PCF/SU2C International Prostate Cancer Dream Team.

Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2.

Supplemental Content

Loading ...
Support Center